Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupDermatologic OncologyradiotherapyDiseaseSquamous Cell Carcinoma of the SkinSubgroupICD10C44.9MeSHCarcinoma, Squamous CellSequenceAlliance A091802: AVEL800/CETU500, CSCC, C1-12 (PID2976) -|- AVEL800, C13-24 (PID2977)C-POST: CEMI350, CSCC, adj., C1-4 (PID2968) -|- CEMI700, C5-10 (PID2969)CETU400, CSCC, C1 (PID2165) -|- CETU250, C2+ (PID2166)CETU400/Radiation, CSCC, C1 (PID2163) -|- CETU250/Radiation, C2+ (PID2164)ChemotherapyChemo-substanceAtezolizumabAvelumabCarboplatinCemiplimabCetuximabCisplatinFluorouracilPanitumumabPembrolizumabPrednisoloneChemo-substanceAtezolizumabAvelumabCarboplatinCemiplimabCetuximabCisplatinFluorouracilPanitumumabPembrolizumabPrednisoloneChemo-substanceAtezolizumabAvelumabCarboplatinCemiplimabCetuximabCisplatinFluorouracilPanitumumabPembrolizumabPrednisoloneChemo-substanceAtezolizumabAvelumabCarboplatinCemiplimabCetuximabCisplatinFluorouracilPanitumumabPembrolizumabPrednisoloneNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclineNaCl 0.9%ParacetamolPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclineNaCl 0.9%ParacetamolPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclineNaCl 0.9%ParacetamolPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclineNaCl 0.9%ParacetamolPotassium chlorideNo. Substances13567Protocol classificationTherapy classificationalternativecurrent standardspecial situationIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseneoadjuvantTherapy intentioncurativecurative or palliativepalliativeRisksAnemia Hb below 8g/dlArthalgiaAstheniaCardiotoxicityColitisConstipationDehydrationDiarrheaDysphagiaEdemaEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHepatotoxicityHyperbilirubinemiaHypercalcemiaHyperkalemiaHypertensionHypomagnesemiaHyponatremiaHypophosphatemiaHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLymphopeniaMucositisNauseaNeuropathyNeutropeniaPneumoniaPneumonitisPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorDivi VFoote MCGrob JGross NDHanna GJJoseph KKhansur T Migden MRNottage MKPreneau SRischin DZandberg DPDiseasefortgeschrittenes oder metastasiertes kutanes Plattenpithelkarzinom, ECOG 0-1fortgeschrittenes oder metastasiertes kutanes Plattenpithelkarzinom, ECOG 0-2kutanes Plattenpithelkarzinom, II, III, oder IV (M0), operabel, ECOG 0-1Kutanes Plattenpithelkarzinom, nicht resektabel, oder metastasiert, ECOG 0-2Kutanes Plattenpithelkarzinom, nicht resektabel, oder metastasiert, nach Nierentransplantation, ECOG 0-2Kutanes Plattenpithelkarzinom, postoperativ und nach Radiatio, hohes Rezidivrisiko, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Plattenepithelkarzinom der Haut, ECOG 0-3Plattenepihelkarzinom der Haut lokal fortgeschritten, inoperabel oder metastasiert, ECOG 0-2Plattenepithelkarzinom der Haut, lokal fortgeschritten, nicht operabel, ECOG 0-2Plattenepithelkarzinom der Haut, lokal fortgeschritten oder Lymphknotenmetastasen, nicht operabel, ECOG 0-2Plattenepithelkarzinom der Haut, lokal fortgeschritten und nicht operabel, oder metastasiert, ECOG 0-2rezidiviertes oder metastasiertes kutanes Plattenepithelkarzinom, ECOG 0-1OriginAix-Marseille University, Marseille, France, KEYNOTE-629Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, AustraliaCenter for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MADepartment of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, CADepartments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer CenterM.D. Anderson Cancer Center, HoustonNantes University Hospital, Nantes, FrancePeter MacCallum Cancer Centre, Melbourne, VIC, Australia, C-POST TrialPrincess Alexandra Hospital, Brisbane; Diamantina Institute, University of Queensland, Brisbane, AustraliaUniversity of Alberta and Cross Cancer Institute, Edmonton, Alberta, CanadaUniversity of Mississippi School of Medicine, JacksonUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Alliance A091802 trialProtocols in Revision 17 protocols foundAtezolizumab 1200, Squamous Cell Carcinoma of the Skin (PID2822 V1.0)Avelumab 800 / Cetuximab 500, Squamous Cell Carcinoma of the Skin, Cycle 1-12 (PID2976 V1.0)Avelumab 800, Squamous Cell Carcinoma of the Skin, Cycle 13-24 (PID2977 V1.0)Carboplatin 2 / Radiation, Squamous Cell Carcinoma of the Skin (PID2178 V1.0)Cemiplimab 350, Squamous Cell Carcinoma of the Skin (PID1379 V2.0)Cemiplimab 350, Squamous Cell Carcinoma of the Skin, adjuvant, cycle 1-4 (PID2968 V1.0)Cemiplimab 350, Squamous Cell Carcinoma of the Skin, after organ transplantation (PID2570 V1.0)Cemiplimab 350, Squamous Cell Carcinoma of the Skin, neoadjuvant (PID2147 V1.0)Cemiplimab 700, Squamous Cell Carcinoma of the Skin, adjuvant, cycle 5-10 (PID2969 V1.0)Cetuximab 250 / Radiation, Squamous Cell Carcinoma of the Skin, Cycle 2+ (PID2164 V1.0)Cetuximab 250, Squamous Cell Carcinoma of the Skin, Cycle 2+ (PID2166 V1.0)Cetuximab 400 / Radiation, Squamous Cell Carcinoma of the Skin, Cycle 1 (PID2163 V1.0)Cetuximab 400, Squamous Cell Carcinoma of the Skin, Cycle 1 (PID2165 V1.0)Cisplatin 100 / Fluorouracil 1000, Squamous Cell Carcinoma of the Skin (PID2385 V1.0)Cisplatin 40 / Radiation, Squamous Cell Carcinoma of the Skin (PID2162 V1.0)Panitumumab 6, Squamous Cell Carcinoma of the Skin (PID2384 V1.0)Pembrolizumab 200, Squamous Cell Carcinoma of the Skin (PID1691 V1.0)
